International journal of clinical oncology · 2026
From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pei Yuxin, Zhang Jiao, Li Chao, Wang Yuanqiang, Yu Qinghua, Chen Wanyi
Аннотация
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, with limited treatment options. Tumor-associated macrophages (TAMs), as key immune cells in the tumor microenvironment, exacerbate the malignancy of TNBC by promoting angiogenesis, metastasis, immune evasion, and drug resistance.
METHOD: We systematically searched PubMed, Web of Science, and ClinicalTrials.gov databases to collect clinical trials targeting TAMs for the treatment of TNBC. Data from completed and ongoing studies were extracted and analyzed, focusing on strategies that inhibit macrophage recruitment, clearance, and reprogramming, as well as their combination with standard therapies.
RESULTS: TAMs in TNBC predominantly exhibit an M2-like pro-tumor phenotype, originating from circulating monocytes and tissue-resident macrophages, and drive progression through multiple pathways. Clinical trials indicate preliminary efficacy for strategies including CSF-1/CSF-1R inhibitors, bisphosphonates, and reprogramming agents-particularly when combined with chemotherapy or immune checkpoint inhibitors-though response rates vary, and optimal regimens remain under investigation.
CONCLUSION: TAMs represent a promising therapeutic target in TNBC. Emerging clinical evidence supports the potential of targeted therapies against them, though further optimization of patient selection and combination strategies is required. This review provides a systematic foundation for advancing treatments targeting TAMs. We confirm that the scientific content remains unchanged.
METHOD: We systematically searched PubMed, Web of Science, and ClinicalTrials.gov databases to collect clinical trials targeting TAMs for the treatment of TNBC. Data from completed and ongoing studies were extracted and analyzed, focusing on strategies that inhibit macrophage recruitment, clearance, and reprogramming, as well as their combination with standard therapies.
RESULTS: TAMs in TNBC predominantly exhibit an M2-like pro-tumor phenotype, originating from circulating monocytes and tissue-resident macrophages, and drive progression through multiple pathways. Clinical trials indicate preliminary efficacy for strategies including CSF-1/CSF-1R inhibitors, bisphosphonates, and reprogramming agents-particularly when combined with chemotherapy or immune checkpoint inhibitors-though response rates vary, and optimal regimens remain under investigation.
CONCLUSION: TAMs represent a promising therapeutic target in TNBC. Emerging clinical evidence supports the potential of targeted therapies against them, though further optimization of patient selection and combination strategies is required. This review provides a systematic foundation for advancing treatments targeting TAMs. We confirm that the scientific content remains unchanged.